The Changing Treatment Landscape for CLL
- CLL treatment has shifted dramatically away from chemotherapy, with targeted therapies like BTK inhibitors (ibrutinib and newer covalent BTK inhibitors) and BCL‑2 inhibitors (venetoclax) showing significantly better outcomes, especially for patients with high‑risk genetic mutations such as 17p deletion or P53 abnormalities.
- Multiple clinical trials over the past decade have demonstrated superior results with these novel agents, leading to more effective, individualized treatment strategies and expanding options beyond traditional chemo‑immunotherapy.
- Patients now benefit from more personalized and sometimes time‑limited treatment plans, guided by genetic features, overall health, and treatment goals — allowing many to achieve strong responses with less toxicity and, in some cases, defined treatment durations.
Dr. Omar Alkharabsheh, a board-certified medical oncologist with Orlando Health Cancer Institute who specializes in blood cancers, explains, “The treatment landscape for CLL in the last 10 years or a decade has really changed and improved patient outcomes.”
Read MoreAn Alternative to Chemotherapy
Dr. Alkharabsheh says, “So the first-in-class Bruton’s tyrosine kinase inhibitor, which is an oral medication that we used in CLL called ibrutinib, has really improved patient outcomes based on many clinical trials”.Since ibrutinib became available, additional targeted therapies have been developed. These include newer BTK inhibitors, which have been studied in comparison with traditional chemo-immunotherapy.
He explains, “Subsequently, we had several phase three trials looking into a second-generation oral therapy. We call them covalent BTK inhibitors that also have shown better results compared to chemo-immunotherapy combinations.”
Expert Resources for CLL Patients
- CLL is Not Considered Curable So Treatment May Resume Years Later
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- CLL Treatment Decision Making — Exploring All Your Options To Find What’s Right For You
- An Oral Medicine for People With Relapsed CLL: Idelalisib
- Active Surveillance For Chronic Lymphocytic Leukemia (CLL)
More Treatment Options
Another treatment option is a class of medications called BCL-2 inhibitors. One example is venetoclax, which can be used with a monoclonal antibody.
Dr. Alkharabsheh explains, “We have another class of medications called BCL-2 or venetoclax that, in combination with a monoclonal antibody, showed better results compared to chemo-immunotherapy.”
The treatment landscape continues to expand as researchers study and develop new combinations of these targeted therapies. For some patients, treatment can also be time-limited, meaning therapy is given for a defined period rather than continuing indefinitely. For example, venetoclax-based combinations can be given for a set duration of about a year, allowing some patients to have a period off treatment after completing therapy.
For patients with CLL, these advances mean treatment decisions can now be more individualized. Factors such as the genetic characteristics of the CLL, overall health, and treatment goals can help guide discussions between patients and their doctors about which approach may be appropriate.
Learn more about SurvivorNet's rigorous medical review process.
